Related references
Note: Only part of the references are listed.Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Hyperphosphorylation of PP2A in colorectal cancer and the potential therapeutic value showed by its forskolin-induced dephosphorylation and activation
Ion Cristobal et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2014)
Systematically Defining Single-Gene Determinants of Response to Neoadjuvant Chemotherapy Reveals Specific Biomarkers
Agnieszka K. Wilkiewicz et al.
CLINICAL CANCER RESEARCH (2014)
Mechanisms Underlying Cancer Growth and Apoptosis by DEK Overexpression in Colorectal Cancer
Lijuan Lin et al.
PLOS ONE (2014)
DEK over expression as an independent biomarker for poor prognosis in colorectal cancer
Lijuan Lin et al.
BMC CANCER (2013)
Oncoprotein DEK as a tissue and urinary biomarker for bladder cancer
Antara Datta et al.
BMC CANCER (2011)
Low cytosine triphosphate synthase 2 expression renders resistance to 5-fluorouracil in colorectal cancer
Wen Lee Tan et al.
CANCER BIOLOGY & THERAPY (2011)
The human DEK oncogene stimulates β-catenin signaling, invasion and mammosphere formation in breast cancer
L. M. Privette Vinnedge et al.
ONCOGENE (2011)
Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis
R. Zarate et al.
BRITISH JOURNAL OF CANCER (2010)
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)
Kei Muro et al.
LANCET ONCOLOGY (2010)
Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy
Ioannis Kostopoulos et al.
BMC CANCER (2009)
Melanoma Proliferation and Chemoresistance Controlled by the DEK Oncogene
Michael S. Khodadoust et al.
CANCER RESEARCH (2009)
Transforming Growth Factor-β3-Induced Smad Signaling Regulates Actin Reorganization During Chondrogenesis of Chick Leg Bud Mesenchymal Cells
Dongkyun Kim et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2009)
Clinicopathological significance of DEK overexpression in serous ovarian tumors
Songying Han et al.
PATHOLOGY INTERNATIONAL (2009)
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer
Jim Cassidy et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Predictive biomarkers of chemotherapy efficacy in colorectal cancer: Results from the UK MRC FOCUS trial
Michael S. Braun et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
DEK overexpression in uterine cervical cancers
Qunying Wu et al.
PATHOLOGY INTERNATIONAL (2008)
Novel 6p rearrangements and recurrent translocation breakpoints in retinoblastoma cell lines identified by spectral karyotyping and mBAND analyses
Jan. A. Paderova et al.
CANCER GENETICS AND CYTOGENETICS (2007)
Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer:: Final report of the Spanish cooperative group for the treatment of digestive tumors trial
Eduardo Diaz-Rubio et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: A final report of the AIO colorectal study group
Rainer Porschen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Identification of differentially expressed genes in tobacco chewing-mediated oral cancer by differential display-polymerase chain reaction
J. K. Nagpal et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2007)
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial
Miriam Koopman et al.
LANCET (2007)
SET and PARP1 remove DEK from chromatin to permit access by the transcription machinery
Matthew J. Gamble et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2007)
Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions
Trisha M. Wise-Draper et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Negative regulation of the RelA/p65 transactivation function by the product of the DEK proto-oncogene
Morgan Sammons et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
DEK expression is controlled by E2F and deregulated in diverse tumor types
Maria Stella Carro et al.
CELL CYCLE (2006)
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC):: a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)
J Souglakos et al.
BRITISH JOURNAL OF CANCER (2006)
SW-620 cells treated with topoisomerase I inhibitor SN-38: gene expression profiling
V Souza et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2005)
The human DEK proto-oncogene is a senescence inhibitor and an upregulated target of high-risk human papillomavirus E7
TM Wise-Draper et al.
JOURNAL OF VIROLOGY (2005)
The DEK protein - an abundant and ubiquitous constituent of mammalian chromatin
T Waldmann et al.
GENE (2004)
Structure-specific binding of the proto-oncogene protein DEK to DNA
T Waldmann et al.
NUCLEIC ACIDS RESEARCH (2003)
The identification of novel therapeutic targets for the treatment of malignant brain tumors
RA Kroes et al.
CANCER LETTERS (2000)
Share Paper
